Nanna Kruse, MSc Danish Medicines Agency

Nanna Aaby Kruse obtained a Master of Science in Pharmacy at the Danish University of Pharmaceutical Science in 1993 and started her work life in the field of malaria vaccine research at the State Serum Institute in Copenhagen.

In 1995, she joined the Danish Medicines Agency, where she is the Team Manager of the biological team in the pharmaceutical Quality Unit. Over the years, she has been the lead Quality/CMC Assessor for the Danish Rapporteur-team in the evaluation of a number of Marketing Authorisation Applications in the Centralized Procedure. She joined CHMP’s Biological Working Group (BWP) at EMA in 2002 and in 2014, she was elected by CHMP to be the BWP Vice-chair. In addition, Nanna is the Danish representative in the Committee for Advanced Therapies (CAT) and member of Biosimilar Working Party (BMWP) and EMA PAT/QbD team. Finally, she is representing BWP/EU in ICHs Expert Working Group for ICH Q12, where she is acting as Regulatory Chair.